DIRS.INFO The most relevant business & tech news

A nurse fills a syringe with malaria vaccine before administering it to an infant at the Lumumba Sub-County hospital in Kisumu, Kenya, July 1, 2022. REUTERS/Baz Ratner/File photo Acquire Licensing RightsGENEVA, Oct 2 (Reuters) - The World Health Organization (WHO) recommended on Monday the use of a second malaria vaccine to curb the life-threatening disease spread to humans by some mosquitoes. recommended the broad use of the world's first malaria vaccine called RTS,S," WHO chief Tedros Adhanom Ghebreyesus told a briefing in Geneva. "Today, it gives me great pleasure to announce that WHO is recommending a second vaccine called R21/Matrix-M to prevent malaria in children at risk of the disease." "GSK has always recognised the need for a second malaria vaccine, but it is increasingly evident that RTS,S, the first ever malaria vaccine and the first ever vaccine against a human parasite, set a strong benchmark," GSK said in a statement.

Persons: Baz Ratner, Tedros Adhanom Ghebreyesus, Tedros, Poonawalla, Takeda, Hanna Nohynek, Gabrielle Tétrault, Farber, Leroy Leo, Gareth Jones, Mark Potter Organizations: Lumumba, REUTERS, Rights, World Health Organization, WHO, Britain's University of Oxford, UNICEF, Serum Institute of India, Reuters, GSK plc, United Nations, GSK, Takeda Pharmaceuticals, Thomson Locations: Kisumu, Kenya, Geneva, Ghana, Malawi, Bengaluru

LONDON (AP) — The World Health Organization authorized a second malaria vaccine on Monday, a decision that could offer countries a cheaper and a more readily available option than the world's first shot against the parasitic disease. “As a malaria researcher, I used to dream of the day we would have a safe and effective vaccine against malaria. Alister Craig, an emeritus professor at the Liverpool School of Tropical Medicine, said he would recommend countries trying to get the GSK vaccine switch to the Oxford vaccine instead. Neither of the malaria vaccines stop transmission so immunization campaigns alone won’t be enough to stop epidemics. In a separate decision, WHO's expert group also authorized the dengue vaccine made by Takeda, which was previously approved by the European Union drug regulator.

Persons: Tedros Adhanom Ghebreyesus, ” Tedros, Tedros, it’s, ”, John Johnson, ” Johnson, Melinda Gates, Alister Craig, Craig, Takeda, Jamey Keaten Organizations: World Health Organization, WHO, Oxford University, Serum Institute of India, Research, Oxford, GSK, Melinda Gates Foundation, Serum, Liverpool School, Tropical, European Union, Associated Press, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: Ghana, Burkina Faso, Africa, Oxford, Bangladesh, Geneva

☆ Can Africa Get Close to Vaccine Independence? Here’s What It Will Take.
▼ + stars: | 2023-04-25 | by ( Stephanie Nolen | ) www.nytimes.com time to read: +2 min

The expense of putting it all in place means that vaccines made in Africa are going to cost significantly more than those from the Indian pharmaceutical industry, which is the major supplier of routine vaccines used in Africa. But the Covid vaccine rollout made clear that despite the low price of Indian-made vaccines, African leaders cannot afford to rely on them. In March 2021, when millions of Serum-made doses of the AstraZeneca vaccine were bound for Africa, the Indian government imposed an export ban and rerouted those vaccines to its own population. The Africa Centers for Disease Control and Prevention says the continent’s existing vaccine market is worth an estimated $1.3 billion and is expected to grow to about $2.4 billion by 2030. Gavi buys half the vaccines used in Africa today.

LONDON, April 21 (Reuters) - African countries are lining up to approve a new vaccine for malaria, with 20 million doses available for them to buy this year, the shot’s manufacturer told Reuters. African countries that do not have extensive resources for drug regulation have previously relied on the U.N. agency to initially review new medicines. "We expect many more countries to come through," Mary Hamel, the WHO's malaria vaccine implementation head, told the expert meeting on Tuesday. “We are committed to making the R21 vaccine available to people who need it most,” Poonawalla said. FUNDING DOUBTSThe moves are a further sign that African countries want to exert their own pharmaceutical oversight after COVID-19 exposed inequity in vaccine supply.

Oxford scientist Adrian Hill said Ghana's drug regulator has approved the vaccine domestically for the age group at highest risk of death from malaria - children aged 5 months to 36 months. Oxford has a deal with Serum Institute of India to produce up to 200 million doses of the vaccine - known as R21 - annually. "This shows how close the world is to having a second approved vaccine to fight malaria," he said. MEETING THE NEEDThe first malaria vaccine, Mosquirix from British drugmaker GSK (GSK.L), was endorsed by the WHO last year after decades of work. Since it began in 2019, 1.2 million children across the three countries have received at least one dose of the Mosquirix vaccine.

☆ S.Africa's Aspen set for deals to revive idled production lines
▼ + stars: | 2023-03-01 | by ( Promit Mukherjee | ) www.reuters.com time to read: +2 min

Aspen had a contract with Johnson & Johnson (JNJ.N) to produce 250 million doses a year of COVID vaccine from its South African plant. It expanded the capacity to 400 million annual doses last year to sell its own branded COVID vaccine Aspenovax anticipating a major flow of orders from African countries. That was a bit of a commercial disappointment," CEO Stephen Saad told Reuters in an interview after its interim earnings. But Saad said the partnerships it was pursuing meant production lines designed for COVID vaccine would start generating returns. The company anticipates a contribution of 2 billion rand ($110.22 million) in calendar year 2024, increasing to 4 billion rand by 2025 under these partnerships, Saad added.

☆ China should set aside politics and look at Covid jab imports, world's largest vaccine maker says
▼ + stars: | 2023-01-16 | by ( Jenni Reid | ) www.cnbc.com time to read: +1 min

China needs to move past political considerations and look at importing Covid-19 jabs to end the pandemic globally, according to the chief executive of the world's latest vaccine manufacturer. The main Covid vaccines approved for use in China are from Sinovac and Sinopharm. These jabs are less effective against the Omicron variant than are other mRNA vaccines, such as Pfizer and BioNTech's, several studies have found. Poonawalla said China's pandemic reaction of 2020 — which included building hospitals and infrastructure and taking precautions — showed that Beijing could respond rapidly. He stressed China's decision not to import vaccines from the U.S., India and elsewhere, which have been "very effective."

☆ China needs to set aside political issues on vaccine imports: Serum Institute of India CEO
▼ + stars: | 2023-01-16 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailChina needs to set aside political issues on vaccine imports: Serum Institute of India CEOAdar Poonawalla, chief executive the Serum Institute of India — the world's largest vaccine manufacturer — told CNBC that China needed to open itself up to health care and vaccines from the U.S., India and elsewhere in order to end the pandemic globally.

☆ Uganda declares itself Ebola-free after swiftly turning tide on outbreak
▼ + stars: | 2023-01-11 | by ( Elias Biryabarema | ) www.reuters.com time to read: +4 min

[1/3] Motorists and cyclists are seen at a traffic light intersection in Kabuusu area of the Lubaga division amid the Ebola outbreak in Kampala, Uganda November 16, 2022. "We have successfully controlled the spread of Ebola in Uganda," Health Minister Jane Ruth Aceng said during a ceremony to mark the outbreak's end. Aceng said this was Uganda's eighth Ebola outbreak since 2000, when the country recorded its first and most deadly one that killed more than half of the 425 people it infected. In the early weeks of the outbreak, cases spread beyond the epicentre of Mubende, 150 km (90 miles) west of the capital Kampala, to several other districts, including Kampala. Unlike the more common strain of the virus, Ebola Zaire, which has been behind several recent epidemics in neighbouring Democratic Republic of Congo, the strain behind Uganda's outbreak, Ebola Sudan, has no proven vaccine.

☆ How this millennial CEO steered the world's largest vaccine maker during the pandemic
▼ + stars: | 2022-12-16 | by ( Olivia Choo | ) www.cnbc.com time to read: +6 min

Adar Poonawalla became the CEO of the world's largest vaccine manufacturer, Serum Institute of India, when he was 30 years old. | Bloomberg | Getty ImagesAdar Poonawalla became the CEO of the world's largest vaccine manufacturer, Serum Institute of India, when he was 30 years old. Today, it is the world's largest vaccine manufacturer — by number of doses produced and sold globally. In 1966, at the age of 25, the elder Poonawalla embarked on a journey to set up the Serum Institute of India. Vaccine production at the Serum Institute of India pharmaceutical plant in Pune, Maharashtra, India.

☆ Gavi rejects Novavax's claim on COVID vaccine deal breach
▼ + stars: | 2022-11-22 | by ( ) www.reuters.com time to read: +2 min

Nov 22 (Reuters) - Global vaccine alliance Gavi on Tuesday rejected Novavax's (NVAX.O) claim that the group had breached an advance purchase agreement to procure 350 million doses of the company's COVID-19 vaccine. Novavax also has a pact with Serum Institute of India for manufacturing a version of the vaccine under the brand Covovax, which would also be supplied to the COVAX facility. Gavi's spokesperson said Serum Institute had a 300 million dose commitment for Covovax, with options for 750 million more doses if needed. A spokesperson for Serum Institute declined to comment. Novavax recently cut its full-year forecast yet again, hurt by late authorizations of its COVID vaccine globally amid a waning demand for shots.

☆ How a horse breeder launched the world's largest vaccine manufacturer
▼ + stars: | 2022-11-21 | by ( Tanvir Gill | ) www.cnbc.com time to read: +1 min

From its humble beginnings as a horse breeding farm in India to becoming the world's largest vaccine manufacturer, Serum Institute of India has undergone rapid growth throughout the decades to reach its exceptional status. The company faced various challenges from getting permits and licenses to not being able to meet the global demand. But today, it is estimated that more than half the children in the world have been administered with their vaccine. After Adar Poonawalla became the CEO in 2011, he noticed the company did not have enough capacity to meet the growing global demand, leading him to invest more in capacity. As the world learns to live with Covid, Serum Institute also has plans to expand its vaccination portfolio and into the Western markets.

☆ Novavax ends COVID vaccine sale agreement with Gavi
▼ + stars: | 2022-11-21 | by ( ) www.reuters.com time to read: +2 min

Nov 21 (Reuters) - Novavax Inc (NVAX.O) said on Monday it had delivered a written notice to Gavi, the Vaccine Alliance, terminating with immediate effect an agreement for the sale of the company's COVID-19 vaccine to low- and middle-income countries. The company cited Gavi's failure to procure the 350 million doses it had agreed to buy in May last year for the COVAX facility. Novavax received a non-refundable advance payment of $350 million from Gavi last year and an additional $350 million this year after the vaccine got the WHO's emergency use listing, the company said. The company had earlier this month cut its full-year forecast yet again, hurt by late authorizations of its vaccine globally. Covovax and Serum's vaccines were the ninth and tenth vaccine, respectively, to get the WHO's emergency listing.

☆ Uganda applies well-honed lessons to new Ebola outbreak
▼ + stars: | 2022-10-22 | by ( Mithil Aggarwal | ) www.nbcnews.com time to read: +7 min

Now, the East African country — lauded for its coronavirus response, which was built around engaging the community and training health officials — is drawing lessons from the first Ebola outbreak in 2004. “They alerted the WHO early and put in the basic pillars of a response early,” Dr. Benjamin Black, an obstetrician, said recalling the West African Ebola response from 2014 to 2016. But Ghebreyesus said Wednesday a clinical trial of vaccines to combat the Sudan species of the Ebola virus could start within weeks. “There’s burnout amongst health workers, health officials and the public across the board in Uganda,” Agoada said. The threadlike Ebola virus spreads when it comes in contact with an infected person’s bodily fluids.

☆ Serum Institute of India discusses vaccine distribution in the U.S. and Europe
▼ + stars: | 2022-09-26 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSerum Institute of India discusses vaccine distribution in the U.S. and EuropeAdar Poonawalla of the Serum Institute of India says the United States has shown "quite a bit of interest" in its vaccine.

The AstraZeneca vaccine received approval from UK regulators in December 2020, and Poonawalla became a household name in India. India's Covid-19 tsunamiBut Poonawalla's plans soon went awry when a second wave of Covid-19 hit India in the spring. But by January 2021, the company had a stockpile of just 70 million doses . SII also says that it has increased its production to 220 million doses a month as of October. SII is also expanding its partnerships, having signed a deal with American biotech firm Novavax to manufacture its Covid-19 vaccine, which is awaiting regulatory approvals.

☆ Apelul OMS către cele mai bogate țări din lume privind vaccinarea anti-COVID la nivel global
▼ + stars: | 2021-05-04 | by ( Publika.Md - Aici Sunt Știrile | ) www.publika.md time to read: +3 min

Organizația Mondială a Sănătății cere statelor G7 să finanțeze vaccinarea împotriva coronavirusului la nivel global, într-un efort de accelerare a imunizării în toată lumea. Cu puţin înainte de acest apel, Covax a anunţat că va achiziţiona 500 de milioane de doze de vaccin antiCOVID Moderna, dar peste 90% din flacoane nu vor fi disponibile înainte de 2022. În afară de Moderna, OMS a omologat vaccinul Pfizer-BioNTech, cele două seruri AstraZeneca fabricate în India şi Coreea de Sud şi cel de la Johnson&Johnson (Janssen). Sistemul s-a lovit de voinţa statelor mai bogate, care în faţa presiunii populaţiei, au procurat cât mai multe doze posibile în detrimentul altora. OMS a invitat ţările cu suficiente vaccinuri să le împărtăşească prin Covax.

Persons: britanic Gordon Brown, El, pandemiei . Brown, Covax, Johnson & Johnson, Janssen, OMS Organizations: Organizația Mondială a Sănătății, OMS, Agerpres, Moderna, Johnson & Locations: SUA, Japonia, Germania, Franţa, Britanie, Canada, Italia, Suediei, Africii, britanic, Regatul Unit, India, Coreea de Sud, Noua Zeelandă, Spania, Suedia, Oxford

„Ţările G7 ar putea mobiliza o parte substanţială din aceste fonduri şi ar putea prelua conducerea eforturilor globale de accelerare a vaccinării pe plan mondial”, a subliniat el. În afară de Moderna, OMS a omologat vaccinul Pfizer-BioNTech, cele două seruri AstraZeneca fabricate în India şi Coreea de Sud şi cel de la Johnson&Johnson (Janssen). Sistemul s-a lovit de voinţa statelor mai bogate, care în faţa presiunii populaţiei, au procurat cât mai multe doze posibile în detrimentul altora. Potrivit medicului Bruce Aylward, responsabil cu dosarul ACT Accelerator al OMS, decizia autorităţilor de la New Delhi a privat Covax de circa 100 milioane de doze de vaccin. Statele Unite, la rândul lor, intenţionează să ofere circa 60 de milioane de doze de vaccin AstraZeneca altor ţări, fără a preciza pentru moment dacă aceste distribuţii vor fi făcute prin Covax.

Persons: britanic Gordon Brown, El, pandemiei . Brown, Covax, Johnson & Johnson, Janssen, OMS, Bruce Aylward Organizations: G7, Moderna, OMS, Johnson & Locations: Suediei, Africii, britanic, Britanie, SUA, Regatul Unit, Japonia, Canada, Covax, India, Coreea de Sud, Franţa, Noua Zeelandă, Spania, Suedia, Oxford, New Delhi, Statele Unite

☆ OMS face apel către țările cele mai bogate din lume să finanțeze vaccinarea la nivel global
▼ + stars: | 2021-05-04 | by ( ) www.jurnal.md time to read: +4 min

Sursa foto: Jurnal.mdOMS face apel către țările cele mai bogate din lume să finanțeze vaccinarea la nivel globalOrganizația Mondială a Sănătății cere statelor G7 să finanțeze vaccinarea împotriva coronavirusului la nivel global, într-un efort de accelerare a imunizării în toată lumea. În afară de Moderna, OMS a omologat vaccinul Pfizer-BioNTech, cele două seruri AstraZeneca fabricate în India şi Coreea de Sud şi cel de la Johnson&Johnson (Janssen). Sistemul s-a lovit de voinţa statelor mai bogate, care în faţa presiunii populaţiei, au procurat cât mai multe doze posibile în detrimentul altora. Dar aceste donaţii nu sunt suficiente, deoarece Covax are nevoie urgentă de 20 de milioane de doze pentru al doilea trimestru, în urma blocării exporturilor indiene. Potrivit medicului Bruce Aylward, responsabil cu dosarul ACT Accelerator al OMS, decizia autorităţilor de la New Delhi a privat Covax de circa 100 milioane de doze de vaccin.

Persons: britanic Gordon Brown, El, pandemiei . Brown, Covax, Johnson & Johnson, Janssen, OMS, Bruce Aylward Organizations: Organizația Mondială a Sănătății, OMS, Agerpres, Moderna, Johnson & Locations: SUA, Japonia, Germania, Franţa, Britanie, Canada, Italia, Suediei, Africii, britanic, Regatul Unit, India, Coreea de Sud, Noua Zeelandă, Spania, Suedia, Oxford, New Delhi, Statele Unite

Vaccinul Moderna se administrează în două doze, chiar dacă noile recomandări prevăd o singură doză dacă persoanele ce urmează a fi imunizate au trecut recent printr-o infectare cu coronavirus. Pe lângă vaccinul Moderna, OMS a omologat şi vaccinul dezvoltat de Pfizer-BioNTech, cele două seruri AstraZeneca fabricate în India şi în Coreea de Sud, precum şi vaccinul produs de compania Johnson & Johnson. În faţa acestei situaţii, OMS a îndemnat ţările care dispun de cantităţi suficiente de vaccinuri să le împartă cu ţările sărace prin intermediul COVAX. Administratorii COVAX speră să dispună de 2 miliarde de doze de vaccinuri anti-Covid până la sfârşitul anului 2021, din care jumătate vor ajunge în 92 de ţări sărace. În total, dacă GAVI îşi va exercita opţiunile suplimentare prevăzute în contractele de achiziţie, acest mecanism şi-a asigurat 3,6 miliarde de doze.

Persons: COVAX, Seth Berkley, Stephane Bancel, Johnson & Johnson, anunţuri, Donaţia, GAVI îşi Organizations: Agerpres, Moderna, OMS, Johnson &, Uniunea Europeană Locations: Geneva, India, Coreea de Sud, Suedia, Oxford, Franţa, Rusia, China

☆ Moderna va livra, prin mecanismul COVAX, 500 de milioane de doze de vaccin anti-Covid pentru țările sărace
▼ + stars: | 2021-05-03 | by ( ) www.jurnal.md time to read: +4 min

Sursa foto: Profimedia ImagesModerna va livra, prin mecanismul COVAX, 500 de milioane de doze de vaccin anti-Covid pentru țările săraceInțiativa globală pentru accesul la vaccinuri împotriva Covid-19, COVAX, va dispune de 500 de milioane de doze de vaccin dezvoltat de compania americană Moderna. Vaccinul Moderna se administrează în două doze, chiar dacă noile recomandări prevăd o singură doză dacă persoanele ce urmează a fi imunizate au trecut recent printr-o infectare cu coronavirus. Pe lângă vaccinul Moderna, OMS a omologat şi vaccinul dezvoltat de Pfizer-BioNTech, cele două seruri AstraZeneca fabricate în India şi în Coreea de Sud, precum şi vaccinul produs de compania Johnson & Johnson. Administratorii COVAX speră să dispună de 2 miliarde de doze de vaccinuri anti-Covid până la sfârşitul anului 2021, din care jumătate vor ajunge în 92 de ţări sărace. În total, dacă GAVI îşi va exercita opţiunile suplimentare prevăzute în contractele de achiziţie, acest mecanism şi-a asigurat 3,6 miliarde de doze.

Persons: COVAX, Seth Berkley, Stephane Bancel, Johnson & Johnson, anunţuri, Donaţia, GAVI îşi Organizations: americană Moderna, Compania, Alianța, Agerpres, Moderna, OMS, Johnson &, Uniunea Europeană Locations: Geneva, India, Coreea de Sud, Suedia, Oxford, Franţa, Rusia, China

☆ ВОЗ разрешила использование вакцины от Moderna
▼ + stars: | 2021-05-01 | by ( ) nokta.md time to read: +1 min

Вакцина Moderna пополняет постоянно растущий список вакцин, одобренных ВОЗ для использования в чрезвычайных ситуациях. Сегодня ВОЗ внесла в список вакцину Moderna COVID-19 (мРНК 1273) для использования в экстренных случаях, что делает ее пятой вакциной, получившей экстренную валидацию ВОЗ. Вакцина уже была рассмотрена Стратегической консультативной группой экспертов ВОЗ по иммунизации (SAGE), которая дает рекомендации по использованию вакцин среди населения (т.е. Вакцина Moderna — это вакцина на основе mNRA. ВОЗ также внесла в список вакцины Pfizer / BioNTech, Astrazeneca-SK Bio, Serum Institute of India и Janssen для экстренного использования.

Persons: India Janssen, nokta Organizations: Moderna, SAGE, mNRA, Pfizer, BioNTech, Astrazeneca, SK, Serum Institute, India, ВОЗ, Всемирная организация здравоохранения, Стратегическая консультативная группа экспертов, Европейское агентство по лекарственным средствам Locations: США, Европейский союз

☆ De ce criza COVID din India contează pentru întreaga lume și cum afectează vaccinarea la nivel mondial
▼ + stars: | 2021-04-28 | by ( ) www.jurnal.md time to read: +4 min

Însă focarul nu este doar o o problemă majoră pentru India, ci este o criză pentru toată lumea. „Și ce se întâmplă acum în India, din păcate, s-a mai întâmplat și în alte țări”, a mai spus dr. Soumya Swaminathan. Însă mai există o altă preocupare majoră cu privire la ratele ridicate de infecție din India: variantele virusului. Acest lucru va avea cu siguranță impact asupra începerii campaniilor de vaccinare din multe țări. „Avem cu adevărat nevoie dublăm vaccinarea cât mai repede posibil sau virusul va scăpacu totul de sub control”, spune Swaminathan.

Persons: ., Pandemia, Jeff Barrett, Sanger, . Sharon Peacock Organizations: Organizația Mondiala a Sănătății ( OMS, BBC, ONU Locations: India, New Delhi, Hong Kong, UK, Institute, Oxford, Indiei

☆ Moldova urmează să inițieze procedura de achiziție a 400.000 de doze de vaccin CoronaVac, produs de SINOVAC
▼ + stars: | 2021-04-09 | by ( Publika.Md - Aici Sunt Știrile | ) www.publika.md time to read: +1 min

Astăzi, a avut loc ședința Comitetului de coordonare a imunizării împotriva COVID-19, în cadrul căreia a fost examinată oferta producătorului de vaccin împotriva COVID-19, SINOVAC BIOTECH LIMITED din China, singurul producător de vaccin care a răspuns solicitărilor adresate de către Centrul pentru Achiziții Publice Centralizate în Sănătate (CAPCS), producătorilor de vaccin.Astfel, în urma analizei ofertei, membrii Comitetului au decis contractarea directă a 400.000 doze de vaccin CoronaVac, produs de SINOVAC, după stabilirea tuturor condițiilor de contractare.Vaccinul CoronaVac este aprobat în 17 țări, inclusiv și în Ucraina. Vaccinul se administrează intramuscular, în 2 doze, la un interval de 28 de zile. Acesta se păstrează la temperatura de 2-8 grade Celsius.Până la ora actuală, CAPCS a lansat două proceduri de achiziție: negociere fără publicare prealabilă a anunțului de participare și licitație deschisă, în cadrul cărora nu a fost depusă nicio ofertă. Invitații au fost transmise producătorilor de vaccin împotriva COVID-19: Pfizer Inc, Moderna Inc, Johnson & Johnson Inc, AstraZeneca PLC, Sinopharm Group Co. Ltd, Russian Direct Investment Fund, Serum Institute of India, AstraZeneca/SK Bioscience Co.Ltd, Sinovac Biotech Ltd. și CanSino Biologics Inc.Menționăm că, CAPCS continuă negocierile directe, exclusiv cu producătorii de vaccin împotriva COVID-19, pentru asigurarea țării cu doze de vaccin în contextul implementării Planului național de imunizare împotriva COVID-19.

Persons: Johnson Organizations: Pfizer, Moderna Inc, Johnson Inc, Sinopharm Group, ., SK Bioscience Locations: China, Ucraina, India, SK Bioscience Co.Ltd, Ltd

☆ CAPCS urmează să inițieze procedura de achiziție a 400 000 de doze de vaccin CoronaVac, produs de SINOVAC BIOTECH LIMITED din China
▼ + stars: | 2021-04-09 | by ( Diana Severin | ) www.zdg.md time to read: +4 min

Ministerul Sănătății, Muncii și Protecției Sociale (MSMPS) anunță că vineri, 9 aprilie, a avut loc ședința Comitetului de coordonare a imunizării împotriva COVID-19, în cadrul căreia a fost examinată oferta producătorului de vaccin împotriva COVID-19, SINOVAC BIOTECH LIMITED din China. Potrivit MSMPS, acesta este singurul producător de vaccin care a răspuns solicitărilor adresate de către Centrul pentru Achiziții Publice Centralizate în Sănătate (CAPCS), producătorilor de vaccin. Astfel, în urma analizei ofertei, membrii Comitetului au decis contractarea directă a 400.000 doze de vaccin CoronaVac, produs de SINOVAC, după stabilirea tuturor condițiilor de contractare. Până la ora actuală, CAPCS a lansat două proceduri de achiziție: negociere fără publicare prealabilă a anunțului de participare și licitație deschisă, în cadrul cărora nu a fost depusă nicio ofertă. Licitația pentru procurarea dozelor de vaccin anti-COVID pentru utilizarea în cadrul planului național de imunizare COVID-19 a eșuat.

Persons: Johnson, MSMPS, CAPCS Organizations: Ministerul Sănătății, Muncii, Protecției Sociale, Pfizer, Moderna Inc, Johnson Inc, Sinopharm Group, ., SK Bioscience, Inc, Agenția Europeană, Organizației Mondiale a Sănătății Locations: China, Ucraina, India, SK Bioscience Co.Ltd, Ltd, Moldova

Search resuls for: "Serum Institute of India"

25 mentions found